All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, BeOne Medicines, Johnson & Johnson, Roche and sobi, and supported through educational grants from Bristol Myers Squibb, Incyte and Lilly. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lymphoma & CLL content recommended for you
ICML 2019 | CHECKMATE 205: Does nivolumab improve the long-term outcomes of patients with advanced stage cHL?
Featured:
Stephen AnsellDuring ICML 2019 in Lugano, Switzerland, the Lymphoma Hub were pleased to speak to Stephen Ansell from Mayo Clinic, Rochester, US, about the CHECKMATE 205 trial. In this interview, Stephen Ansell discusses whether nivolumab improves the long-term outcomes of patients with advanced stage classical Hodgkin lymphoma (cHL).
Initial results of the trial showed a very good progression-free survival (PFS), with updated results showing a two-year PFS of 83%. Despite having dropped from the nine-month PFS, Stephen Ansell mentioned that the results were still promising, with exciting results ahead for novel agents that are being used alongside chemotherapy.
CHECKMATE 205: does nivolumab improve the long-term outcomes of patients with advanced stage cHL?
Your opinion matters
In your experience, when do most CRS/ICANS events occur after lisocabtagene maraleucel infusion?